Skip to main content

Table 1 Summary of the characteristics of the included studies

From: Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis

Author/yearNPhysical statusTNM stageInterventionDuration (cycle)OutcomesMethods score
TCTC
Ye L et al., 2017 [25]3030NRIIIb-IVTP + XAPI (60 ml/d, d1–10)TP18
Hu XL et al., 2017 [26]5353NRIIIb-IVGP + XAPI (20 ml/d, d1–15)GP49
Gu N et al., 2016 [27]3939NRIII-IVGP + XAPI (22 ml/d, d1–22)GP17
Liu JR et al., 2016 [28]3030ZPS ≤ 3IIIb-IVGP + XAPI (40 ml/d, d1–14)GP27
Li XG et al., 2016 [29]6458KPS > 70IIIb-IVGP + XAPI (80 ml/d, d1–8)GP47
Li QL et al., 2016 [30]3636KPS > 70IIIb-IVGP + XAPI (40–60 ml/d, d1–15)GP29
Yao J, 2016 [31]5353KPS ≥ 61IIIb-IVTP + XAPI (20 ml/d, d1–21)TP27
Song Y et al., 2016 [32]4040NRIIIb-IVGP/NP + XAPI (40 ml/d, d1–15)GP/NP18
Li YL et al., 2015 [33]3332KPS ≥ 60IIIb-IVTP + XAPI (60 ml/d, d1–15)TP2⑩⑪8
Mei CR et al., 2015 [34]3033KPS ≥ 60IIIb-IVTP + XAPI (20 ml/d, d1–14)TP28
Shen LW et al., 2015 [35]2828KPS ≥ 60III-IVTP + XAPI (40–60 ml/d, d1–15)TP28
Ai L et al., 2015 [36]3332KPS ≥ 60IIIb-IVTP + XAPI (60 ml/d, d1–14)TP27
Shi L et al., 2015 [37]2626NRIIIb-IVTP + XAPI (60 ml/d, d1–14)TP37
Xia GA, 2013 [38]3939KPS ≥ 50IIIb-IVTP + XAPI (40 ml/d, d1–14)TP27
Fang H et al., 2013 [39]4343KPS > 70IIIb-IVGP + XAPI (4 ml/d, d1–8)GP39
Yang WQ et al., 2013 [40]3737PS 0–2IIIb-IVDP + XAPI (60 ml/d, d1–28)DP29
Zhang FY et al., 2011 [41]2424KPS > 50IIIb-IVGP + XAPI (40–60 ml/d, d1–15)GP28
Yang H et al., 2011 [42]3030KPS ≥ 60IIIb-IVNP + XAPI (60 ml/d, d1–7)NP27
Bai RL, 2010 [43]3636KPS ≥ 60IIIa-IVNP + XAPI (60 ml/d, d1–15)NP17
Li J et al., 2009 [44]3838KPS > 70IIIb-IVGP + XAPI (40 ml/d, d1–15)GP28
Wang K et al., 2009 [45]2828KPS > 50IIIb-IVNP + XAPI (20–60 ml/d, d1–15)NP28
Wang WY et al., 2009 [46]2729KPS ≥ 70IIIb-IVTP + XAPI (80 ml/d, d1–7)TP27
Song CP, 2008 [47]3636KPS ≥ 60IIIa-IVNP + XAPI (60 ml/d, d1–15)NP27
Huang ZQ et al., 2007 [48]3032KPS ≥ 50IIIb-IVGP/TC/NP + XAPI (60 ml/d, d1–15)GP/TP/NP2⑩⑫8
  1. NR Not reported, DP Docetaxel plus Cisplatin, GP Gemcitabine plus Cisplatin, NP Navelbine plus Cisplatin, TP Taxol plus Cisplatin; outcomes ORR; KPS; leukopenia; thrombocytopenia; anemia; nausea and vomiting; liver function; kidney function; diarrhea; ⑩ constipation; ⑪ fatigue; ⑫ immune function
\